The review concludes that CD20-targeted chimeric antigen receptor (CAR) T-cell therapy is an option worth exploring, despite potential safety concerns that warrant more extensive research. CAR T-cell ...
Clinical outcomes of cytomegalovirus infection among patients receiving chimeric antigen receptor T cell therapy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results